Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA

Autor:	Mina, Awad, Pavit, Singh, Olga, Hilas
Rok vydání:	2017
Předmět:	Departments nervous system musculoskeletal neural and ocular physiology hemic and lymphatic diseases macromolecular substances
Zdroj:	PT : a peer-reviewed journal for formulary management. 42(1)
ISSN:	1052-1372
Popis:	Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::875061882f844d6a1d9b771c8d2e926b https://pubmed.ncbi.nlm.nih.gov/28090158 Zobrazit plný text záznamu